Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 13/20 | 0.42 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25981002 | 0.87 | MAPT (0.47) | KDM4EALDH1A1TSHRHSD17B10CSNK2A1 | |
| SCHEMBL17941944 | 0.85 | CSNK2A1 (0.51) | KDM4EALDH1A1TSHRHSD17B10CSNK2A1 | |
| SCHEMBL25982124 | 0.81 | NAMPT (0.60) | KDM4EALDH1A1NAMPT | |
| SCHEMBL17941862 | 0.80 | MET (0.50) | KDM4EALDH1A1TSHRHSD17B10CSNK2A1 | |
| SCHEMBL17941962 | 0.79 | NAMPT (0.53) | NAMPT | |
| SCHEMBL6601501 | 0.75 | MAPT (0.59) | KDM4EALDH1A1TSHRHSD17B10ALOX15 | |
| SCHEMBL733132 | 0.75 | TSHR (0.50) | ALDH1A1TSHRHSD17B10CREBBP | |
| SCHEMBL17942033 | 0.75 | NAMPT (0.64) | ALDH1A1NAMPT | |
| SCHEMBL28175260 | 0.73 | ADORA1 (0.54) | KDM4EALDH1A1 | |
| SCHEMBL25977852 | 0.73 | HTT (0.49) | KDM4EALDH1A1HSD17B10CSNK2A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250145599-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | MRJA THERAPEUTICS, INC. | 2025-05-08 | — | — | US | disclosed |
| CN-118974019-A | Certain chemical entities, compositions and methods | 瑞图恩制药公司 | 2024-11-15 | — | — | CN | disclosed |
| WO-2023150663-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | RETUNE PHARMA INC. (US) | 2023-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250145599-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | IGF1R, IGFBP1, IGFBP2 | KDM4E 3842/4885ALDH1A1 826/4885TSHR 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.